BRISBANE, Australia--(BUSINESS WIRE)--Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) today announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease (IBD). This milestone brings Microba’s drug candidate MAP 315 into clinical development as a potential new treatment option for the millions of people suffering from ulcerative colitis.
Microba Launches Next Generation Healthcare Testing
Australian startup Microba Life Sciences has announced that leading medical diagnostics provider Sonic Healthcare has agreed to invest $17.8 million to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5 million in Microba.
BRISBANE, Australia--(BUSINESS WIRE)--Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) has signed a strategic partnership agreement (“Agreement”) with nib Holdings Limited (ASX: NHF) backed digital healthcare company Midnight Health, to deliver a personalised health service to the Australian consumer market.
BRISBANE, Australia--(BUSINESS WIRE)--Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is excited to announce it has identified three therapeutic leads for the Company’s Immuno-Oncology program significantly earlier than expected. This will enable preclinical animal studies to be brought forward to the end of calendar year 2022 which is approximately 12 months ahead of schedule.